Skip to main content
. Author manuscript; available in PMC: 2020 Apr 1.
Published in final edited form as: Am J Kidney Dis. 2019 Apr;73(4):437–458. doi: 10.1053/j.ajkd.2019.01.007

Table 4.

BP Target Studies in Populations With CKD

Study Description BP Groups Mean f/u, y Kidney End Point
SPRINT subgroup with CKD73 (N = 2,646) Aged ≥50 y, high CVD risk, UPCR < 1 g/g; eGFR > 20 mL/min/1.73 m2, no DM SBP < 120 vs <140 mm Hg 3.3 HR, 0.90 (95% Cl, 0.44, 1.83) for composite of ≥50% decline in eGFR oi ESRD
REIN-295 (N = 338) Aged 18–70 y, urine protein excretion 1 −3 g/d with CLcr < 45 mL/min or ≥3 g/d with CLcr < 70 mL/min SBP/DBP < 130/80 mm Hg vs DBP < 90 mm Hg 1.6 HR, 1.00 (95% Cl, 0.61–1.64) for ESRD
AASK75 trial phase (N = 1,094) 18–70 y, African Americans with clinically attributed hypertensive CKD, GFR 20–65 mL/min/1.73 m2, UPCR < 2.5 g/g, no DM MAP ≤ 92 vs 102–107 mm Hg 4.1 HR, 1.06 (95% Cl, 0.89–1.27) for ESRD
AASK trial phase with UPCR > 0.22 g/g75 (N = 357) 4.1 HR, 0.76 (95% Cl, 0.55–1.04) for doubling of Scr or ESRD
AASK trial & cohort phases75 (N = 691) 9.1 HR, 0.95 (95% Cl, 0.78–1.15) for ESRD
AASK trial & cohort phases75 with UPCR > 0.22 g/g (N = 357) 9.1 HR, 0.76 (95% Cl, 0.58–0.99) for doubling of Scr or ESRD
MDRD Study trial phase88 (N = 840) Aged 18–70 y with GFR 13–55 mL/min/1.73 m2 MAP < 92 mm Hg if age ≤ 60 y & MAP < 98 mm Hg if age ≤ 61 y vs 107 mm Hg if age < 60 y & <113 mm Hg if age ≥ 61 y 2.2 HR, 0.78 (95% Cl, 0.66–0.93) for kidney failure
MDRD Study trial & cohort phases73 (N = 840) 9.2 HR, 0.68 (95% Cl, 0.57–0.82) for ESRD

Abbreviations: AASK, African American Study of Kidney Disease and Hypertension; BP, blood pressure; CI, confidence interval; CKD, chronic kidney disease; CLcr creatinine clearance; CVD, cardiovascular disease; DBP, diastolic blood pressure; DM, diabetes mellitus; (e)GFR, (estimated) glomerular filtration rate; ESRD, end-stage renal disease; HR, hazard ratio; MAP, mean arterial pressure; MDRD, Modification of Diet in Renal Disease; REIN-2, Blood Pressure Control for Renoprotection in Patients With Non-Diabetic Chronic Renal Disease; SBP, systolic blood pressure; Scr, serum creatinine; SPRINT, Systolic Blood Pressure Intervention Trial; UPCR, urinary protein-creatinine ratio.